Author

A. Viros

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 4 Organism:human· 4 Research Focus:cancer & tumor microenvironment· 3 Research Focus:differential expression· 3 Research Focus:gene regulatory network inference· 3 Approach:statistical model· 3 Research Focus:cell type annotation· 2 Approach:experimental assay· 2

Frequent Co-Authors

T. Budden· 4 shared C. Gaudy-Marqueste· 3 shared A. Malliri· 2 shared C. Earnshaw· 2 shared E. Nagore· 2 shared L. Motta· 2 shared S. Craig· 2 shared S. Furney· 2 shared

Activity by Year

2019-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

T. Budden

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer

W. J. McDaid, L. Wilson, H. Adderley, M. J. Baker, J. Searle, L. Ginn, T. Budden, M. Aldea, A. Marinello, J. Aredo, A. Viros, B. Besse, H. A. Wakelee, F. Blackhall, C. R. Lindsay, A. Malliri

This study compares KRASG12C and KRASG12D mutant NSCLC models, finding that KRASG12D relies more on the PI3K-AKT-mTOR pathway, suggesting tailored combination therapies.

bioRxiv · Sep 20, 2023Cancer Biology

Female immunity protects from cutaneous squamous cell carcinoma

T. Budden, C. Gaudy-Marqueste, S. Craig, Y. Hu, C. Earnshaw, S. Gurung, A. Ra, V. Akhras, P. Shenjere, R. Green, L. Jamieson, J. Lear, L. Motta, C. Caulin, D. Oudit, , A. Viros

The paper shows women are more protected from aggressive cutaneous squamous cell carcinoma due to stronger immune activation compared to men.

bioRxiv · Jan 28, 2021Cancer Biology

MOLECULAR LANDSCAPE OF OLD AGE MELANOMA BY SURVIVAL AND IMMUNOTHERAPY RESPONSE

S. P. Smith, E. Nagore, T. Budden, R. Kumar, R. Marais, C. Gaudy-Marqueste, A. Viros

This study identifies age-specific mutations and transcriptomic changes in melanoma linked to survival and immunotherapy response, showing that certain mutations improve survival in older patients treated with immunotherapy.

bioRxiv · Jan 27, 2021 · PreprintCancer Biology

Ultraviolet light-induced collagen degradation inhibits melanoma invasion

T. Budden, C. Gaudy-Marqueste, A. Porter, E. Kay, S. Gurung, C. Earnshaw, K. Roeck, S. Craig, V. Traves, J. Krutmann, P. Muller, L. Motta, S. Zanivan, A. Malliri, S. Furney, , A. Viros

This study shows UVR-induced collagen degradation by fibroblasts reduces melanoma invasion and improves survival, but melanoma-associated fibroblasts can restore invasion by increasing collagen synthesis.

bioRxiv · Jan 27, 2021Cancer Biology

Biological sex and age shape melanoma tumour evolution

M. Lotz, S. J. Furney, A. Viros

This study uses a mathematical model to show how age and sex influence mutation accumulation in melanoma genomes, revealing differences in mutation rates and types between sexes and across age groups.

bioRxiv · Nov 1, 2019 · PreprintCancer Biology